Search
Poor blood circulation
go.drugbank.com/conditions/DBCOND0108559Drugs: NonivamideSynonyms: Poor blood circulationLysine
go.drugbank.com/drugs/DB00123ApprovedInvestigationalNutraceuticalLysine is a base, as are arginine and histidine. The ε-amino group acts as a site for hydrogen binding and a general base in catalysis. … O-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell.
Mixtures: 21st Century L-Lysine 600mg Tablet, ONE A DAY TABLETCategories: Detoxifying Agents for Antineoplastic TreatmentQuetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalInitially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. … It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].[A2189]
Categories: Antidepressive Agents Indicated for DepressionProducts: Pro-quetiapine, QUETIAPINA EGPhenylpropanolamine
go.drugbank.com/drugs/DB00397ApprovedVet approvedWithdrawnIt has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. … Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor.
Mixtures: COUGH - EN, COUGH - EN PLUSCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Nasal Decongestants for Systemic UseVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigational[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. … After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSumatriptan
go.drugbank.com/drugs/DB00669ApprovedInvestigationalSumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. … [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.
Synonyms: (3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamideCategories: Monoamine Oxidase A SubstratesCeftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalCeftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for … the convenience of daily or twice-daily dosing.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: CEFTRIAXONE EG, ROCEPHIN 1 GR IM ENJ. COZ. HAZ. ICIN TOZ ICEREN FLAKONDoxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigationalDoxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. … [A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Categories: Drugs Used in Benign Prostatic Hypertrophy, Antihypertensive Agents Indicated for HypertensionProducts: DOXAZOSINA EG, DOXAZOSIN 1 COR 1A PHARMAIbandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805] … Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].
Categories: Drugs for Treatment of Bone DiseasesProducts: OSTIVEA 3mg/3ml Solution for IV Injection in Pre-filled Syringe, ACIDO IBANDRONICO EGMesalazine
go.drugbank.com/drugs/DB00244ApprovedInvestigationalAlthough demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent … An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022].
Products: MESALAZINA EG, MESALAZINA EG STADA